Amgen
Amgen Ready for a ReboundOn a graphical level, a bullish divergence has formed between the price and the Commodity Channel Index (CCI). A close above the black trendline will give the entry signal (long) on Amgen.
First target area $ 179.65/182.47, while the stop loss below the last low ($ 168.44). I leave you free to decide the level on the basis of your money management.
Live example of a market cycle euphoria phase coming to an endWhat happens when a car keeps going forward, but slows down?
Same principle.
Here is a quick summary about market cycles:
www.investopedia.com
If 200$ was indeed the top, what we should see next are lower highs. And a long bear market.
It has already been going up with less strength for a while. Retail investors getting dumped on.
Well I say retail investors, but institutions too, they don't do anything special.
The difference is institutions will be the first to "panic" sell when shit hits the fan.
It will be too hard for retail to do, but trust me, when something is hard to do, most of the time it is a very good idea to do it.
Making the hard choices is what the masses cannot do, and being able to do that gives you an incredible edge.
That... or being logical to start with and not emotional lol... I personally fail to see the logic. That should not even be a hard decision, just binary.
Oh and by the way, having your money managed by pro's does not shield you if you invest in overvalued crap (not saying AMGEN is crap).
Novogratz crypto fund dropped by 30%, his clients money is gone.
"Strength in numbers" does not apply to finance :p
Think of it rather like cattle going to the slaughterhouse. Do they have strength in numbers?
Get ready to see Amgen feature on bagholderquotes, in a few months, by 2020 at the very most:
twitter.com
Arrowhead Pharmaceuticals Massive Institutional AccumulationStock tanked last year because hep b trials killed a chimp, so they shelved project to focus on Amgen and RNAi program therapies.
Buy half now, buy the other half on a pullback. Fucking beautiful chart. BEAUTIFUL
Only short to medium term risk is dilution, which is a very real possibility . The buying is just SO strong though, wow. BEAUTIFUL, like, it's ....just,.....its a beautiful chart. So firm and consistent, and green, with heavy volume. For it to have responded so strongly after a major investor left is very indicative of positive outcomes in the future.
Late 2016
-Amgen to Receive Worldwide Exclusive License to Arrowhead's RNAi ARC-LPA Program
-Amgen Receives Exclusive License Option to RNAi Therapy for Undisclosed Cardiovascular Target
-Arrowhead to Receive $56.5 Million in Upfront Payments and Initial Equity Investment and up to an Additional $617 Million in ------Potential Milestone and Equity Payments
up to $617 million in option payments, and development, regulatory and sales milestone payments
"Arrowhead's expertise in RNAi makes them a valuable partner as we translate genetic discoveries into potential therapies that can improve health outcomes for patients," said Sean E. Harper, M.D., executive vice president of Research and Development at Amgen. "This collaboration builds upon our commitment to cardiovascular disease with targets that we believe are uniquely suited for RNAi-based therapy."
"We have made great advances to our proprietary subcutaneous RNAi delivery vehicle and in RNAi trigger modification and stabilization that enable rapid development of new RNAi therapeutics across multiple disease areas," said Christopher Anzalone, Ph.D., president and chief executive officer at Arrowhead. "Our capabilities and platform technologies are becoming increasingly validated, so we feel that now is a great time to expand the reach of our technologies and partner with other companies to maximize the value of our assets. We are thrilled to be working with Amgen, one of the world's leading biotechnology companies, on this collaboration. Amgen's extensive development, regulatory, and commercial expertise makes them an ideal partner, and we look forward to a long and productive relationship."
Amgen: have a break?Amgen is a good performer the latest weeks. We see that indicators (Elliot Wave Oscillator, not given in this chart) give us positive and negative signs. First of all the power of the bounce becomes weaker. On the other hand there still is a gap and Amgen is trying to fill this. If Amgen breaks the declining blue line, the power of the uptrend increases. Above the 180 dollar level, the next target is attacking the 194. But first, let's see where the bulls arrive... I'm in at a price of 160 dollar
